Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
Institute for Clinical Medicine, University of Oslo, Norway.
Mol Oncol. 2019 Dec;13(12):2604-2615. doi: 10.1002/1878-0261.12571. Epub 2019 Sep 22.
Dysregulation of microRNAs is a common mechanism in the development of lung cancer, but the relationship between microRNAs and expression subtypes in non-small-cell lung cancer (NSCLC) is poorly explored. Here, we analyzed microRNA expression from 241 NSCLC samples and correlated this with the expression subtypes of adenocarcinomas (AD) and squamous cell carcinomas (SCC) to identify microRNAs specific for each subtype. Gene set variation analysis and the hallmark gene set were utilized to calculate gene set scores specific for each sample, and these were further correlated with the expression of the subtype-specific microRNAs. In ADs, we identified nine aberrantly regulated microRNAs in the terminal respiratory unit (TRU), three in the proximal inflammatory (PI), and nine in the proximal proliferative subtype (PP). In SCCs, 1, 5, 5, and 9 microRNAs were significantly dysregulated in the basal, primitive, classical, and secretory subtypes, respectively. The subtype-specific microRNAs were highly correlated to specific gene sets, and a distinct pattern of biological processes with high immune activity for the AD PI and SCC secretory subtypes, and upregulation of cell cycle-related processes in AD PP, SCC primitive, and SCC classical subtypes were found. Several in silico predicted targets within the gene sets were identified for the subtype-specific microRNAs, underpinning the findings. The results were significantly validated in the LUAD (n = 492) and LUSC (n = 380) TCGA dataset (False discovery rates-corrected P-value < 0.05). Our study provides novel insight into how expression subtypes determined with discrete biological processes may be regulated by subtype-specific microRNAs. These results may have importance for the development of combinatory therapeutic strategies for lung cancer patients.
microRNAs 失调是肺癌发生的常见机制,但 microRNAs 与非小细胞肺癌 (NSCLC) 表达亚型之间的关系尚未得到充分探索。在这里,我们分析了 241 个 NSCLC 样本中的 microRNA 表达,并将其与腺癌 (AD) 和鳞状细胞癌 (SCC) 的表达亚型相关联,以确定每个亚型特异性的 microRNAs。我们利用基因集变异分析和标志性基因集来计算每个样本的基因集得分,并进一步将其与亚型特异性 microRNAs 的表达相关联。在 AD 中,我们在终末呼吸单位 (TRU) 中鉴定出 9 个异常调节的 microRNAs,在近端炎症 (PI) 中鉴定出 3 个,在近端增殖亚型 (PP) 中鉴定出 9 个。在 SCC 中,分别在基底、原始、经典和分泌亚型中发现 1、5、5 和 9 个 microRNAs 显著失调。亚型特异性 microRNAs 与特定基因集高度相关,并且在 AD PI 和 SCC 分泌亚型中发现了具有高免疫活性的独特生物学过程模式,而在 AD PP、SCC 原始和 SCC 经典亚型中则上调了与细胞周期相关的过程。在基因集中,对亚型特异性 microRNAs 进行了多个计算预测靶标鉴定,支持了这些发现。在 LUAD(n=492)和 LUSC(n=380)TCGA 数据集(校正后的错误发现率<0.05)中,这些结果得到了显著验证。我们的研究为具有离散生物学过程的表达亚型如何受亚型特异性 microRNAs 调节提供了新的见解。这些结果对于为肺癌患者制定组合治疗策略可能具有重要意义。